NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Lynk Pharmaceuticals

Lynk Pharmaceuticals

Private
HangzhouHealthcare & Life Scienceshttps://lynkpharma.com/

Last Round

Series C

Extension

Sep 21, 2023

Est. Valuation

$467.6M

Total Funding Raised

$154.95M

Company Overview

Lynk Pharmaceuticals is a clinical-stage biotechnology company that develops innovative small molecule drugs to treat tumors, autoimmune diseases, and inflammatory conditions.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Revenue Share, Services & Consulting

AI Layer

Application

Keywords

small-molecule drugsJAK inhibitordrug discoveryclinical-stage biotechautoimmune disease treatmentbiopharmainflammatory diseaseJanus kinaseoncologydrug licensingclinical trialscomputational drug designAI-augmented R&Dbiotech startupTYK2

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Lynk Pharmaceuticals Comparables

Compare Lynk Pharmaceuticals with similar companies based on industry and business-model similarity.

Lynk Pharmaceuticals comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Alumis
84%
Sareum Holdings plc
78%
Aclaris Therapeutics
77%

Lynk Pharmaceuticals Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series C ExtensionSep 21, 2023
Series CMay 31, 2023
Series BAug 27, 2021
Series A ExtensionDec 1, 2020
Series A ExtensionDec 1, 2020
Series A
Jan 1, 2020

Key People

Founding team and executive leadership

陈䶮

首席运营官 共同创始人(Chief Operation Officer Co-Founder)

Founding Team

Lynk Pharmaceuticals Investors

Notable investors and investment history

Lynk Pharmaceuticals investors
InvestorRounds
New Alliance CapitalSeries C Extension, Series B
Kaitai CapitalAngel, Seed, Series A
健壹资本Angel, Seed
Tailong InvestmentSeries C
Legend CapitalSeries B, Series A Extension
Howbuy Primary FundSeries C Extension
Liando InvestmentSeries C Extension, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 1, 2025

    Preparing for NDA submission and international audits.

  • Sep 21, 2023

    $17M round led by China Grand Prosperity Investment.

Lynk Pharmaceuticals Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Lynk Pharmaceuticals Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersHangzhou
Employee Range21
Year Founded2018
Last FundingSep 21, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.